Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders

BACKGROUND: With ocrelizumab another drug is available for the treatment of multiple sclerosis (MS). Little is known on the long-term use of ocrelizumab on immune cell subsets, and no surrogate markers are available. Rituximab (RTX) has been in off-label use for the treatment of MS, neuromyelitis op...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Neurol
Autors principals: Ellrichmann, Gisa, Bolz, Jan, Peschke, Maren, Duscha, Alexander, Hellwig, Kerstin, Lee, De-Hyung, Linker, Ralf A., Gold, Ralf, Haghikia, Aiden
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2018
Matèries:
Original Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6342886/
https://ncbi.nlm.nih.gov/pubmed/30377816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00415-018-9092-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars